TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells.
TLR3 and TLR9 recognize the pathogen-associated microbial patterns dsRNA and unmethylated DNA, respectively. The recent discovery that these receptors also recognize endogenous ligands from necrotic material has drawn increased attention to their involvement in autoimmunity. Th cell cytokines IL-17A and IL-21 have been assigned with pivotal roles in the regulation of such autoimmune diseases. IL-17A is the hallmark cytokine of the recently discovered proinflammatory Th cell subset T(H)17. By contrast, the expression of IL-21 does not seem to be limited to a single distinct Th cell subset. We investigated the expression of IL-17A and IL-21 in human CD4+ T cells in response to stimulation with the TLR3 ligand polyinosinic:polycytidylic acid (poly(I:C)) and the TLR9 ligand CpG. We discovered that poly(I:C) induced synthesis of both IL-17A and IL-21. Moreover, we found that poly(I:C) was able to drive the differentiation of naive Th cells into an IL-21 but not into an IL-17A-producing phenotype and did this without affecting the levels of transcription factors T-bet, GATA-3, or retinoic acid receptor-related orphan receptor C. Finally, we found that the IL-21-producing cells that were differentiated in response to poly(I:C) expressed the chemokine receptor CXCR3, which is important in the recruitment of T cells into inflamed joints in rheumatoid arthritis. This is the first report to show that the TLR3 ligand poly(I:C) can directly induce the synthesis of IL-17A and IL-21 and drive differentiation of human naive CD4+ T cells.
Holm
Christian K
CK
Institute of Medical Microbiology and Immunology, University of Aarhus, Aarhus, Denmark. chol@immunology.au.dk
Petersen
Charlotte C
CC
Hvid
Malene
M
Petersen
Line
L
Paludan
Søren R
SR
Deleuran
Bent
B
Hokland
Marianne
M
D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000201:enzymology / Q000276:immunology / Q000378:metabolism; D002478:Cells, Cultured; D018899:CpG Islands / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D020381:Interleukin-17 / Q000096:biosynthesis*; D007378:Interleukins / Q000096:biosynthesis*; D008024:Ligands; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology; D016328:NF-kappa B / Q000502:physiology; D018384:Oxidative Stress / Q000276:immunology; D011070:Poly I-C / Q000378:metabolism* / Q000494:pharmacology; D011493:Protein Kinase C / Q000502:physiology; D054398:Receptors, CCR4 / Q000235:genetics / Q000378:metabolism; D054367:Receptors, CXCR3 / Q000096:biosynthesis / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism*; D051196:Toll-Like Receptor 3 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism* / Q000502:physiology; D051217:Toll-Like Receptor 9 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D000098546:Interleukin-21
C515354:CCR4 protein, human; C515187:CXCR3 protein, human; D018836:Inflammation Mediators; D020381:Interleukin-17; D007378:Interleukins; D008024:Ligands; D016328:NF-kappa B; D054398:Receptors, CCR4; D054367:Receptors, CXCR3; C495344:TLR3 protein, human; C495371:TLR9 protein, human; D051196:Toll-Like Receptor 3; D051217:Toll-Like Receptor 9; D011493:Protein Kinase C; D000098546:Interleukin-21; D011070:Poly I-C